Navigation Links
Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment

NEW YORK and NASSAU, The Bahamas, April 30 /PRNewswire-FirstCall/ -- Prospero Group (PRPG) invested into the Private Placement Plan of Fincor (FINC) through a 1:1 share split. Prospero Group a leading company in the field of Water Technologies enlarges thru Fincor its portfolio with the new ACTRx Malaria and Dengue fever treatment. Fincor also acquired the WETTECH and Advanced Cavitation Technologies.

Prospero Group enlarges its technology portfolio with ACTRx, which combines several natural drugs to fight Malaria and Dengue fever. Prospero Group's largest shareholder, Fincor acquired a majority on ACTRx International Inc. to become the premier global supplier of Malaria and Dengue cures, preventatives, maintenance and information products and services.

Both Malaria and Dengue fever appear in the human landscape and seem to have only nebulous solutions that work sporadically in over one half of the countries in the world. Yet there are countries that have enjoyed the disappearance of both of these mosquito born diseases. Prospero Group's intention is to research, review and objectively resolve the issues that keep these diseases active in our global society.

Fincor also acquired WETTECH marketed as Prospero Water Technologies and the Advanced Cavitation Technology.

Prospero Group intends to make further strategic acquisitions of proven, reliable and innovative technologies to its portfolio.

It was decided by the Board Members of Prospero Group on Friday, April 24, 2009 to invest into the Private Placement Plan of Fincor Inc. through a 1:1 share split of Prospero Group shareholdings.

About Prospero Group: Prospero Group is a U.S. and Bahamian technology development company whose primary focus is developing and producing technologies for potable water and alternative energy systems. Our market developments are concentrated in The Bahamas, United States of America, Latin America, Europe and Far East. One of the actual projects is to enable customers to sell "Green" water and energy products. The basis of the Prospero Water Technologies campaign will be its Advanced Cavitation Technology (ACT), "WETTECH", Planets Purest Water and other Air Water generating machines.

About Fincor Inc.: Fincor Inc. is a technology and pharmaceutical company. It has recently acquired ACTRx International Inc. which produces Malaria and Dengue fever drugs in order to become the premier global supplier of Malaria and Dengue cures, preventatives, maintenance and information products and services. Fincor Inc. also acquired Advanced Cavitation Technology ("WETTECH"), which produces 1000 gallons (200 liters) per hour of high purity distilled water. Using this technology, consistently delivers the highest purity product water at the lowest overall cost with a minimum of maintenance.

Allowing the liquid to become the heat source, rather than a hot surface as in conventional applications eliminates the problems of scale build-up and fouling associated with the heating of impure liquids. So the device provides efficient, simple, inexpensive and reliable sources of distilled potable water for residential, commercial and industrial use. The Cavitation Technology operates at a very low operating cost and is the only water purification of its type to be fully clean-in-place (CIP) capable at such large capacity of delivering potable water.

SOURCE Prospero Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. International Coal Group Is Lead Sponsor for West Virginia Susan G. Komen Race For The Cure
2. Pandemic Flu Preparedness Guides for Families, Businesses, Medical Providers, and Community Groups Released by Trust for Americas Health
3. Top Policy Groups Take Action to Create Healthy Communities, Prevent Childhood Obesity
4. Unsung Heroes of Health Care Reform?: $36 Billion in Annual Savings Linked to Group Purchasing Organizations in Major Survey of Over 400 Hospitals
5. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
6. Salmon of the Americas Responds to PEW Environmental Group
7. Less Than a Year After CDC Announced the U.S. HIV Epidemic Is Much Larger Than Previously Thought, Publics Sense of Urgency Is Down, Even Among Some Higher Risk Groups
8. Guidelines for medical home demonstrations released by major physician groups
9. The Quantum Group Announces Filing of Utility Patent Application
10. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
11. New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... Dental Association meeting in Washington D.C. revolved around the fact that proper dental care, ... The talk stressed the link between periodontal disease (more commonly referred to as gum ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the ... Table 1-1 ). More than 3.7 billion people under the age of 50 ... (HSV-1), according to WHO's first global estimates of HSV-1 infection . , "The data ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
Breaking Medicine Technology: